OSE Immunotherapeutics - Steady progress on all fronts
OSE Immunotherapeutics (OSE) and its three pharma partners have made progress with all key clinical and preclinical assets. The final analysis of the data from the most advanced trial in OSE’s R&D pipeline, the Phase III ATALANTE-1 study investigating lung cancer vaccine Tedopi, revealed a potential path to market and OSE is now aiming to discuss the data with regulators. The three partnered assets – BI 765063, S95011/OSE-127 and VEL-101/FR104 – are in different stages of clinical development and generate relatively steady licensing fee income. Our updated valuation is €319m or €17.5 per share (from €16.2 per share).
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
- OSE Immunotherapeutics - Steady progress on all fronts03 May 2022